{"id":"NCT00793624","sponsor":"Boehringer Ingelheim","briefTitle":"Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I","officialTitle":"A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 µg [2 Actuations of 2.5 ug] and 10 ug [2 Actuations of 5 ug]) Delivered by the Respimat® Inhaler, and 48 Weeks of Twice Daily Foradil® (12 µg) Delivered by the Aerolizer® Inhaler, in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-02","primaryCompletion":"2010-12","completion":null,"firstPosted":"2008-11-19","resultsPosted":"2014-06-05","lastUpdate":"2014-06-27"},"enrollment":906,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"interventions":[{"type":"DRUG","name":"Olodaterol (BI 1744)","otherNames":[]},{"type":"DRUG","name":"Olodaterol (BI 1744)","otherNames":[]},{"type":"DRUG","name":"Formoterol","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Olodaterol (BI 1744) Low","type":"EXPERIMENTAL"},{"label":"Olodaterol (BI 1744) High","type":"EXPERIMENTAL"},{"label":"Formoterol 12mcg","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to assess the long-term efficacy and safety of once daily treatment of BI 1744 CL inhalation solution (5 and 10 mcg) delivered via the Respimat® inhaler, in patients with COPD.","primaryOutcome":{"measure":"Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 24 Weeks","timeFrame":"1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Week 24","effectByArm":[{"arm":"Placebo","deltaMin":-0.009,"sd":0.016},{"arm":"Olo 5 mcg qd","deltaMin":0.142,"sd":0.015},{"arm":"Olo 10 mcg qd","deltaMin":0.156,"sd":0.015},{"arm":"Form 12 mcg","deltaMin":0.168,"sd":0.015}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG003","p":"<0.0001"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":93,"countries":["Argentina","Brazil","Canada","Croatia","Czechia","Denmark","Finland","Germany","Hong Kong","India","Italy","Malaysia","Norway","Philippines","South Africa","South Korea","Spain","Sweden","Thailand","Ukraine"]},"refs":{"pmids":["32943047","32848381","30077810","25045258"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":31,"n":225},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis","Upper respiratory tract infection","Cough","Dyspnoea"]}}